What is cutaneous squamous cell carcinoma? Cutaneous squamous cell carcinoma (cSCC) is cancer of the skin’s squamous cells. It can invade deeper tissue and spread to lymph nodes or other sites, so a persistent or changing growth needs examination and, when indicated, biopsy. NCI skin SCC description.
Confidence: high for tissue-based diagnosis and care matched to the actual cancer. This guide concentrates on invasive skin SCC, distinguishing it from SCC in situ and squamous cancers of internal or mucosal sites. Attributed clinical guidance and regulatory indications are separated from financially independent treatment-outcome evidence.
- Invasive skin SCC is distinct from SCC in situ, actinic keratosis and squamous cancers of other organs.
- Persistent scaly lesions, changing scars and non-healing sores need assessment, even without pain.
- Depth, differentiation, nerve involvement and immune suppression can alter the clinical risk assessment.
- Surgery and selected additional treatment depend on the actual disease; postoperative immunotherapy is not for every removed SCC.
- Serious immune reactions and transplant rejection require coordinated safety planning; supplements do not replace cancer care.
Table of contents
- Evidence summary
- Skin SCC, SCC in situ and actinic keratosis are different findings
- Symptoms: a persistent scaly patch, growth or changing scar
- UV exposure, immune suppression and individual risk
- Biopsy and risk assessment: depth is different from visible size
- Local treatment: excision, Mohs and selected radiotherapy
- Systemic and postoperative immunotherapy: the indication matters
- Serious medicine risks and the transplant boundary
- Interactions, supplements and nutrition
- Protection, skin review and follow-up after treatment
- Research limits: independent outcomes need more than a mechanism
- Funding and source roles
- Frequently asked questions
- Sources and funding notes
Evidence summary
Clinical descriptions, care guidance and independently established treatment outcomes have different evidentiary roles. The table identifies what the reviewed sources can support and which financial or clinical questions remain unresolved.
| Question / approach | Evidence reviewed | Funding / conflicts | Interpretation / limits |
|---|---|---|---|
| What does the biopsy finding mean? | NHS testing, NCI distinctions and selected 2018 pathology framework. | Public-source page/study gaps; guideline authors have relevant commercial ties, Tier 3/C. | Separate precursor/in-situ findings from invasion; no home stage score. |
| What local treatment is considered? | Current NHS and NCI procedural descriptions; bounded dated guideline. | Clinical framework does not clear underlying trial funding. | Selected excision/Mohs/radiotherapy; surface care cannot be assumed suitable for invasion. |
| What changed for postoperative medicine? | Actual October 2025 FDA status and August 2026 maker label. | Regulator public/user-fee routes; maker data and C-POST support Tier 4/D. | Indication/safety only; no independently cleared effect estimate. |
| What about supplements or app screening? | NCI diet, interactions, prevention and screening context. | Complete product-study and contributor financial chains unclosed. | No treatment replacement, app diagnosis or personal supplement regimen established. |
Skin SCC, SCC in situ and actinic keratosis are different findings
BCC and SCC are different types of non-melanoma skin cancer; the precise pathology name matters for care. “Squamous cell carcinoma” also appears in other organ diagnoses, but a skin-cancer plan should not be transferred automatically to them. Current NHS definition.
SCC in situ describes abnormal cells confined to the epidermis. Actinic keratosis is not cancer, although it can become SCC. Neither term is interchangeable with invasive cSCC, which extends into underlying tissue. NCI skin-layer and precursor distinctions.
Confirm the biopsy diagnosis. A topical treatment for a surface lesion is not evidence that invasive cancer can be managed identically. Resolve an incomplete or uncertain sample with the service.
Symptoms: a persistent scaly patch, growth or changing scar
A lesion may get bigger, change colour or texture, hurt, itch, bleed, crust or repeatedly scab. Non-melanoma lesions can have different colours across skin tones. The NHS advises assessment of concerning changes and explains that urgent referral does not itself confirm cancer. September 2026 symptom and referral guidance.
AAD describes scaly patches, firm growths and non-healing sores. Pain, numbness or a change within a longstanding scar or wound may also matter; a lesion can be painless. Supported descriptive symptom context.
Report rapid change, altered sensation or a new lump near a treated area. A photograph documents location and change; it cannot establish nerve or lymph-node involvement, or clear surgical margins.
UV exposure, immune suppression and individual risk
UV radiation from sunlight and tanning devices is a major cause. Older age and skin that burns easily increase risk, but non-melanoma cancer also occurs in people with brown or black skin. Risk history cannot prove or exclude an individual diagnosis. NHS risk context.
Immune suppression can make skin SCC more aggressive. Transplant medicines and a history of a persistent wound or scar should therefore be included in the assessment. Do not stop essential immune-suppressing treatment yourself. Immune and wound context.
Report whether the lesion appeared in an old burn, irradiated area or previous skin-cancer site. These details inform assessment; a sun-protected location does not establish a harmless cause.
Biopsy and risk assessment: depth is different from visible size
Specialists may use magnification and obtain a skin sample for laboratory examination. After diagnosis, selected scans, lymph-gland tests or blood tests may be needed because SCC can spread. Further investigation depends on the cancer and its circumstances rather than a single test for every lesion. Current NHS testing pathway.
The 2018 AAD guideline considers recurrence, rapid growth and immune suppression, alongside pathology such as differentiation, depth, nerve involvement and surgical margins. These features are assessed together; this guide provides no home risk score or numeric staging cutoff. Selected dated pathology framework.
Ask what the tissue report establishes and whether the sample is sufficient to plan care. “Well differentiated” and “poorly differentiated” describe a microscopic finding, rather than whether the surface looks tidy. Keep the biopsy site and original pathology record available if another service is involved. A small visible lesion or painless growth cannot substitute for this assessment.
Ask what a nerve finding or unclear margin means for the next step. One phrase cannot determine whether a scan is needed without the clinical picture.
Local treatment: excision, Mohs and selected radiotherapy
Surgery is a main treatment for non-melanoma skin cancer. Selected patients receive radiotherapy, including when the location makes surgery difficult, the person is too unwell for surgery, or additional treatment is considered after removal. A larger wound may need a graft or other repair. Current local-treatment guidance.
Excision removes the cancer with surrounding tissue. Mohs surgery removes and examines thin layers at their edges, continuing until the examined margins show no cancer. This is a selected margin-control approach, not a requirement for every cSCC. NCI surgical distinction.
The 2018 guideline does not treat topical creams or light-based treatment for surface lesions as established substitutes for surgery for invasive cSCC. Its historical scope does not supply a complete current medicine menu. Invasive versus surface-treatment boundary.
Clarify how removal will be assessed and repair will protect function. Treatment for a different lesion is not a personal plan. This review supplies no excision width, radiation course or procedure-success ranking.
Systemic and postoperative immunotherapy: the indication matters
On 8 October 2025, the US FDA approved cemiplimab for selected adults with cSCC at high risk of recurrence after surgery and radiation. This postoperative indication does not apply automatically to every localized tumour or replace those earlier treatments. Actual FDA status and scope.
The August 2026 US label also includes selected adults with metastatic or locally advanced cSCC who are not candidates for curative surgery or radiation. Different treatment goals and eligibility cannot be collapsed into a single “immunotherapy for skin cancer” rule. Current manufacturer label indication.
A discussion about care after successful local treatment concerns the risk of future recurrence; treatment for established spread concerns existing disease. Ask which situation the team is addressing, what options are available locally and which assessments are needed before a medicine is considered.
The primary EU C-POST registry identifies Regeneron as both commercial sponsor and monetary/material supporter. Its outcome claims are excluded from this review’s independent efficacy verdict; a regulator or registry hosting the information does not change the original funding. Actual study-support record.
Serious medicine risks and the transplant boundary
Cemiplimab can cause severe or fatal immune reactions in multiple organs, including lung, bowel, liver, kidney and endocrine inflammation, and solid-organ transplant rejection. Reactions can occur after treatment has stopped. Pregnancy and breastfeeding require medicine-specific advice. Selected August 2026 safety warnings.
Tell oncology about organ transplantation, autoimmune illness, immune-suppressing drugs, pregnancy plans and other clinical teams before prescribing. Immune treatment is not a simple way to strengthen immunity, and its effects are not limited to the tumour. Coordinated assessment matters especially when another organ depends on preventing rejection.
New breathing problems, severe diarrhoea, jaundice or a serious skin reaction need prompt assessment using the team’s urgent-contact instructions. A rapidly severe reaction warrants emergency help; do not wait for the next infusion or attempt to manage it with a supplement. Selected warning-symptom context.
The service should explain expected effects, serious warning signs and the appropriate contact route before treatment. This guide does not give a toxicity grade, a steroid regimen or reassurance based on a low reported percentage. A warning list cannot predict an individual reaction.
Interactions, supplements and nutrition
NCI describes drug-specific interactions involving foods and concentrated supplements, including St John’s wort and grapefruit. Check the actual anticancer prescription and ingredient list with the pharmacist rather than adopting a universal food ban. Selected interaction context.
Nutrition support is different from a claim that a food, vitamin, herb or restrictive diet cures cancer or prevents its return. NCI advises discussing supplements with the cancer team. This review establishes no independently cleared supplement replacement for cSCC treatment. Nutrition and supplement boundary.
Also report skin creams, nonprescription products and prescriptions from other clinics. Ask the surgical team about medicines that affect a procedure, including blood-thinning medicines, without stopping them independently. A “natural”, immune-support or skin-health label does not tell the team what ingredients or exposure it contains.
A prevention claim needs its own human evidence and finance assessment. This article does not prescribe a nicotinamide regimen, antioxidant product or supplement combination for someone with a skin-cancer history. Laboratory anticancer activity is not evidence that the marketed oral product controls an invasive tumour.
Protection, skin review and follow-up after treatment
Practical NHS protection includes limiting UV exposure, protective clothing, suitable sunscreen and avoiding tanning devices. Protection supports risk reduction; it does not treat a lesion already present. Advice must fit local UV conditions rather than a worldwide clock-time rule. Protection context.
NCI distinguishes protection guidance from uncertainty in particular cancer-endpoint studies. This guide gives no quantitative guarantee, sunscreen-brand ranking or claim that an oral product substitutes for UV protection. Prevention-evidence limits.
Asymptomatic screening differs from assessment of a suspicious lesion. False-positive and false-negative findings and biopsy harms are possible; skin-assessment apps require further large-scale validation. Screening and app limits.
Keep an individualized follow-up plan and treatment summary, including pathology, procedures, medicines and contacts. New symptoms should be reported between visits; the disease and care received determine the schedule. Follow-up-care planning.
For cSCC, retain the lesion location, margin result and any lymph-node findings. Ask who reviews the treated site, other skin lesions and medicine effects. A new growth near the scar and a new lesion elsewhere require assessment rather than an assumption that both have the same cause. No universal scan or visit interval is supplied here.
Research limits: independent outcomes need more than a mechanism
Clinical trials study prevention, diagnosis, treatment and ways to manage cancer-related problems. Participation requires eligibility and consent; a listing does not establish superior care for a particular person. Trial role.
For invasive cSCC, relevant human outcomes include durable cancer control, recurrence or spread, function, quality of life and treatment harms. A cell-culture response, animal tumour shrinkage or a pathway explanation does not establish these benefits. A short-term response and prevention of recurrence are different questions.
The actual 2018 guideline is used only for bounded pathology and invasive-treatment context. Current FDA status and August 2026 label safety are dated separately. Sponsored disease education and the maker-supported C-POST study do not supply independent product efficacy, while the guideline’s disclosed author relationships remain visible in the funding map.
Funding and source roles
Research funding at a glance
30 disclosure entries. The counts below summarize independence tiers explicitly assigned in this article. They count disclosures, not studies, funding amounts or evidence quality.
Consult this article’s source and funding notes for named funders, countries, relationships and exceptions where available. Institutional backing, researcher interests and trial sponsorship are separate questions. Public funding alone does not establish independence; commercial ties alone do not prove a claim false. This overview is not a new financial audit.
The source-specific map separates documented institutional funding from disease-page payments and trial sponsorship. Unknown allocations remain unknown. A public agency, charity or academic address does not by itself establish independent treatment efficacy.
| Source | Funding / backers | Country / jurisdiction | Independence | Credibility / incentives / gaps |
|---|---|---|---|---|
| NHS non-melanoma skin cancer definition | National website policy; fiscal route and limits in the separate policy row. Exact contributor and study finances unclosed. | United Kingdom; national NHS website, not an individual provider trust. | Tier 2 public clinical context, provisional. | B, provisional — actual 16 September 2026 body read; clinical accountability supports checking. Page allocation, expert interests, simplification and local-pathway limits remain. |
| NHS non-melanoma skin cancer symptoms | National website policy; fiscal route and limits in the separate policy row. Exact contributor and study finances unclosed. | United Kingdom; national NHS website, not an individual provider trust. | Tier 2 public clinical context, provisional. | B, provisional — actual 16 September 2026 body read; clinical accountability supports checking. Page allocation, expert interests, simplification and local-pathway limits remain. |
| NHS non-melanoma skin cancer causes | National website policy; fiscal route and limits in the separate policy row. Exact contributor and study finances unclosed. | United Kingdom; national NHS website, not an individual provider trust. | Tier 2 public clinical context, provisional. | B, provisional — actual 16 September 2026 body read; clinical accountability supports checking. Page allocation, expert interests, simplification and local-pathway limits remain. |
| NHS non-melanoma skin cancer tests | National website policy; fiscal route and limits in the separate policy row. Exact contributor and study finances unclosed. | United Kingdom; national NHS website, not an individual provider trust. | Tier 2 public clinical context, provisional. | B, provisional — actual 16 September 2026 body read; clinical accountability supports checking. Page allocation, expert interests, simplification and local-pathway limits remain. |
| NHS non-melanoma skin cancer treatment | National website policy; fiscal route and limits in the separate policy row. Exact contributor and study finances unclosed. | United Kingdom; national NHS website, not an individual provider trust. | Tier 2 public clinical context, provisional. | B, provisional — actual 16 September 2026 body read; clinical accountability supports checking. Page allocation, expert interests, simplification and local-pathway limits remain. |
| NCI skin cancer patient PDQ | Derived professional version and named lead; separate January/February 2026 disclosure records consulting/advisory interests. NCI fiscal routes are in dedicated profiles. Later relationships are not payment attribution to this page; source-trial contracts unclosed. | United States; NCI/NIH/HHS, Bethesda, Maryland; federal jurisdiction. | Tier 3 derived source with disclosed professional reviewer relationships. | C, provisional — actual patient derivation and professional lead credit read. Khan’s later relevant interests and incompletely public member/study finances limit independence; no page payment or product efficacy inferred. |
| NCI skin cancer health-professional PDQ | Federal appropriations and gift routes; named lead reviewer Shaheer A. Khan. January/February 2026 disclosure reports relevant consulting/advisory ties. Later interests do not prove payment for this page; underlying study contracts unclosed. | United States; NCI/NIH/HHS, Bethesda, Maryland; federal jurisdiction. | Tier 3 source with disclosed reviewer commercial relationships. | C, provisional — actual credited reviewer and separate later declaration read. Expert review supports checking; known relevant interests and incompletely public PDQ member/trial finances limit independence. |
| NCI skin cancer prevention patient PDQ | Congressional appropriations; separate gift routes. Page, contributor and underlying-study allocations unclosed. | United States; NCI/NIH/HHS, Bethesda, Maryland; federal jurisdiction. | Tier 2 clinical context, provisional; underlying studies not financially cleared. | B, provisional — expert review and public accountability support accuracy; updated 16 May 2025; PDQ board-specific interests are not fully published. Not a treatment guideline. |
| NCI skin cancer screening patient PDQ | Congressional appropriations; separate gift routes. Page, contributor and underlying-study allocations unclosed. | United States; NCI/NIH/HHS, Bethesda, Maryland; federal jurisdiction. | Tier 2 clinical context, provisional; underlying studies not financially cleared. | B, provisional — expert review and public accountability support accuracy; actual selected body read; PDQ board-specific interests are not fully published. Not a treatment guideline. |
| NCI diets and supplements | Congressional appropriations; separate gift routes. Page, contributor and underlying-study allocations unclosed. | United States; NCI/NIH/HHS, Bethesda, Maryland; federal jurisdiction. | Tier 2 clinical context, provisional; underlying studies not financially cleared. | B, provisional — expert review and public accountability support accuracy; posted 30 October 2024; Institutional mission and unclosed page/contributor interests remain. |
| NCI food and supplement interactions PDQ | Congressional appropriations; separate gift routes. Page, contributor and underlying-study allocations unclosed. | United States; NCI/NIH/HHS, Bethesda, Maryland; federal jurisdiction. | Tier 2 clinical context, provisional; underlying studies not financially cleared. | B, provisional — expert review and public accountability support accuracy; updated 25 April 2024; PDQ board-specific interests are not fully published. Not a treatment guideline. |
| NCI follow-up medical care | Congressional appropriations; separate gift routes. Page, contributor and underlying-study allocations unclosed. | United States; NCI/NIH/HHS, Bethesda, Maryland; federal jurisdiction. | Tier 2 clinical context, provisional; underlying studies not financially cleared. | B, provisional — expert review and public accountability support accuracy; actual selected body read; Institutional mission and unclosed page/contributor interests remain. |
| NCI clinical-trial overview | Congressional appropriations; separate gift routes. Page, contributor and underlying-study allocations unclosed. | United States; NCI/NIH/HHS, Bethesda, Maryland; federal jurisdiction. | Tier 2 clinical context, provisional; underlying studies not financially cleared. | B, provisional — expert review and public accountability support accuracy; actual selected body read; Institutional mission and unclosed page/contributor interests remain. |
| AAD cutaneous SCC patient guide | Disease page explicitly acknowledges Regeneron support, while stating AAD developed the content. Society income and corporate routes are separate. Exact grant, contract and contributor payments unclosed. | United States; AAD, Rosemont, Illinois. Regeneron headquarters documented separately in Tarrytown, New York. | Tier 4 industry-supported education; excluded independent efficacy. | D for independence — actual 13 January 2026 page and support footer read. Relevant product seller has commercial incentives; educational accountability does not remove sponsorship. Descriptive/safety context only. |
| AAD 2018 invasive cutaneous SCC guideline | Original reports no funding source and prohibits pharmaceutical funding of production. Authors nevertheless disclose relevant fees/research ties: Armstrong includes Regeneron and other makers; Sekulic Roche/Genentech; Olenecki BMS, Genentech, Pfizer and others. Full individual amounts and underlying-trial chains unclosed. | United States; AAD framework and contributor institutions. Complete author/backer jurisdictions not audited. | Tier 3 guideline with disclosed commercial author relationships. | C, provisional — actual full original and declarations read. Disclosure/recusal accountability supports checking; 2018 date, author interests and study gaps limit independence. Surface and mucosal cancers are outside its scope. |
| AAD/AADA combined 2024 audited financial statements | Actual full 36-page audited report, selected note 2: dues, meetings/exhibits, journal royalties, educational products, grants and contributions. Corporate grants and licensing routes documented; exact disease-page sums unclosed. | United States; combined American Academy of Dermatology and Association. | Tier 3 institutional financial self-report with external audit. | B, provisional — audit and accounting detail support accuracy; institution reports its own finances, 2024 period and missing current page allocation remain. |
| AAD corporate-support programme | Actual programme page describes sponsorship/grants and corporate participation. Current 2026 heading and 2025 programme-support footer have different periods; no complete donor or contract ledger inferred. | United States; AAD, Rosemont, Illinois. | Tier 3 institutional funding self-report. | B, provisional — explicit commercial route; fundraising incentives, incomplete amounts and disease-page allocation remain. |
| AAD office/contact information | Society contact self-report; revenue routes are in separate audit and support profiles. | United States; 9500 W. Bryn Mawr Avenue, Suite 500, Rosemont, Illinois. Additional Washington office. | Tier 3 institutional identity self-report. | B, provisional — actual office body read; location does not establish evidence independence. |
| Shaheer A. Khan January/February 2026 financial disclosure | Actual three-page publisher original identifies advisory/consulting relationships with Regeneron, Ideaya Biosciences, Replimune and Immunocore. Interview/article financing and complete amounts unclosed; not payment attribution to May 2025 NCI skin page. | United States; disclosed author at Zucker School of Medicine, Hofstra University, Hempstead, New York. Complete backer jurisdictions not traced here. | Tier 3 author with relevant commercial relationships; financial-only. | C, provisional — explicit dated declaration helps accuracy. Full remuneration, publisher backers and page-period allocation unclosed; no clinical effect adopted. |
| Regeneron second-quarter 2026 financial report | Actual 30 July 2026 company report: product and collaboration revenues, including Libtayo, and shareholder/distribution routes. Complete ownership/control, education grants and disease-page allocations unclosed. | United States; headquarters separately documented in Tarrytown, New York. International commercial collaborations. | Tier 4 therapeutic-product seller self-report. | D for independence — direct commercial and investor incentives; dated financial disclosure is useful for tracing, not medicine efficacy. |
| Regeneron company locations | Company location self-report; actual income routes are in the separate financial profile. | United States; 777 Old Saw Mill River Road, Tarrytown, New York. No inference that all manufacturing occurs here. | Tier 4 product-seller identity source. | D for independence — company accurately identifying itself remains commercially interested. Manufacturing/subcontractor and ownership chains unclosed. |
| Cemiplimab US prescribing information, revised August 2026 | Regeneron manufacturer prescribing information held by NLM/DailyMed. Repository hosting does not remove applicant sponsorship. Complete trial funding/author contracts unclosed. | United States label/jurisdiction; Regeneron headquarters in Tarrytown, New York. Complete manufacturing chain not inferred. | Tier 4 manufacturer/applicant-derived medicine information. | D for independence — regulatory safety accountability is valuable, but seller/application data remain interested. Selected current warnings and indication only; numerical outcomes excluded. |
| FDA FY2026 operating plan | Actual five-page plan distinguishes public budget authority and regulated-industry user fees, including drugs/biologics. No exact application or page fee assigned. | United States; federal FDA/HHS, Silver Spring, Maryland. | Tier 3 regulator financial self-report. | B, provisional — fiscal transparency and statutory accountability; fee routes, policy priorities and page allocation remain. |
| FDA visitor and headquarters information | Official institutional location self-report; public/fee routes in separate operating-plan profile. | United States; White Oak campus, Silver Spring, Maryland. | Tier 3 regulator identity self-report. | B, provisional — actual body read; regulator location does not identify a drug manufacturing site. |
| FDA postoperative cSCC approval, 8 October 2025 | FDA public/user-fee routes and regulator location separately traced. Maker-applicant C-POST evidence remains Tier 4/D; individual reviewer/application allocations unclosed. | United States; FDA/HHS, Silver Spring, Maryland. US status does not establish worldwide access. | Tier 2 regulator status context, provisional; applicant efficacy excluded. | B, provisional for status — actual original indication read. Regulatory accountability supports accuracy; fee routes and applicant-data dependence remain. |
| Primary EU C-POST trial registry support record | Regeneron Pharmaceuticals is the commercial sponsor and the stated monetary/material supporter. Regulatory repository does not remove maker sponsorship; full investigator, contract and payment chain unclosed. | United States sponsor, Tarrytown, New York; Italian record in EU registry. International trial, complete site jurisdictions not assessed. | Tier 4 manufacturer-supported trial record; efficacy excluded. | D for independence — actual sponsor/support fields read and useful for attribution. Commercial incentives and unclosed individual finances; no numerical outcome adopted. |
| NCI budget and appropriations, May 2026 | Congressional funding through HHS/NIH. Enacted appropriations and future requests differ; no disease-page amount assigned. | United States; NCI/NIH/HHS, Bethesda, Maryland. | Tier 3 institutional financial self-report. | B, provisional — actual budget process and dated body read; fiscal accountability, budget priorities and missing page allocation. |
| NCI Gift Fund and contribution routes, August 2025 | Public gifts/Gift Fund and Breast Cancer Research Stamp route separate from Congress. Named page donors and complete accepted receipts unclosed. | United States; 9000 Rockville Pike, Bethesda, Maryland; federal NCI. | Tier 3 institutional financial self-report. | B, provisional — actual contribution and headquarters text read; no named donor control or page sponsorship inferred. |
| NCI PDQ editorial boards, November 2022 | NCI support; non-government member honoraria/travel expenses. Declarations and recusal required; specific conflicts not publicly required. | United States; NCI, Bethesda, with international board contributors. | Tier 3 institutional process and payment self-report. | B, provisional — actual dated policy read; editorial independence does not clear member interests or sponsored underlying trials. |
| NHS national content policy, October 2022 | DHSC funding; policy states no advertising or corporate sponsorship. Full page/expert receipts unclosed. | United Kingdom; national NHS website. | Tier 3 financial/editorial self-report. | B, provisional — actual funding/accuracy policy read; next review due October 2025 passed. Not a provider-trust accounts profile. |
Frequently asked questions
Is cutaneous SCC the same as SCC in the lung or mouth? No. This guide concerns skin cancer; the site and pathology determine the care pathway. Do not transfer its treatment plan to another organ.
Is actinic keratosis already invasive cancer? No. It is a noncancerous skin condition that may become SCC. The biopsy diagnosis still needs to distinguish a precursor, in-situ disease and invasion. NCI distinction.
Can skin SCC turn into melanoma? They arise from different skin cell types. A person can develop another skin cancer, but that does not mean SCC became melanoma. Cell-type distinction.
Does every removed SCC need cemiplimab? No. The US postoperative approval is for selected adults at high recurrence risk after surgery and radiation, not every removed lesion. FDA indication.
Can a cream for a surface lesion replace invasive-cancer care? Do not make that substitution. Invasion changes the assessment; the team needs the actual biopsy finding and appropriate treatment plan.
Can I wait until follow-up if a new problem appears? Report new concerns between visits. Serious breathing difficulty or a rapidly severe treatment reaction needs urgent assessment, using the team’s emergency instructions.
Sources and funding notes
Current NHS bodies were reviewed 16 September 2026. Selected NCI clinical/supportive-care originals were read; patient skin PDQ derives from the professional version naming Khan. His dated January/February 2026 commercial declaration is not page-payment attribution. The full 2018 AAD guideline and commercial author declarations supply limited pathology and invasive-treatment context, not a complete 2026 drug menu. The January 2026 AAD patient page explicitly acknowledges Regeneron support; supported efficacy claims are excluded. Actual FDA October 2025 status, August 2026 manufacturer safety/indication information and the primary EU trial-support record are separated. The full AAD 2024 audit and regulator/company financial originals document institutional routes, not exact disease-page grants or individual treatment-trial payments. Numerical outcomes, personal doses, margins, scan schedules and supplement regimens are excluded. Complete original-study and contributor financial chains remain unclosed; US/UK context is not worldwide licensing.
- NHS non-melanoma skin cancer definition — BCC versus SCC scope.
- NHS non-melanoma skin cancer symptoms — Changing or persistent lesions and referral.
- NHS non-melanoma skin cancer causes — UV risk and practical sun protection.
- NHS non-melanoma skin cancer tests — Biopsy and individually selected further tests.
- NHS non-melanoma skin cancer treatment — Selected surgery, radiotherapy and local/systemic care families.
- NCI skin cancer patient PDQ — Selected pathology, local behaviour and procedure context.
- NCI skin cancer health-professional PDQ — Selected mechanism and care categories; no independent product-effect estimate.
- NCI skin cancer prevention patient PDQ — Prevention endpoint uncertainty, not a brand ranking.
- NCI skin cancer screening patient PDQ — Asymptomatic screening versus diagnosis; app and biopsy limits.
- NCI diets and supplements — Nutrition versus unestablished cancer-cure claims.
- NCI food and supplement interactions PDQ — Selected drug-specific food/ingredient interactions.
- NCI follow-up medical care — Individual follow-up plan and between-visit contact.
- NCI clinical-trial overview — Research participation and consent, not established individual benefit.
- AAD cutaneous SCC patient guide — Selected appearance and immune/wound context; supported outcome claims excluded.
- AAD 2018 invasive cutaneous SCC guideline — Selected pathology and invasive-treatment context; no current drug menu or numerical outcome adopted.
- AAD/AADA combined 2024 audited financial statements — Society revenue routes only; not clinical evidence.
- AAD corporate-support programme — Corporate support route; not evidence of a treatment effect.
- AAD office/contact information — Institutional location only.
- Shaheer A. Khan January/February 2026 financial disclosure — Financial declaration only; uveal-melanoma treatment claims not used.
- Regeneron second-quarter 2026 financial report — Manufacturer revenue and commercial interests only.
- Regeneron company locations — Manufacturer headquarters only, not a production-chain audit.
- Cemiplimab US prescribing information, revised August 2026 — Selected indication and serious safety warnings; no efficacy or dose conclusion.
- FDA FY2026 operating plan — Actual regulator funding route only.
- FDA visitor and headquarters information — Regulator location only.
- FDA postoperative cSCC approval, 8 October 2025 — Actual US indication/status only; sponsor outcome estimates excluded.
- Primary EU C-POST trial registry support record — Study sponsor and monetary/material support only, not a product benefit conclusion.
- NCI budget and appropriations, May 2026 — Institutional appropriation route only.
- NCI Gift Fund and contribution routes, August 2025 — Separate gift route and office identity; no clinical evidence.
- NCI PDQ editorial boards, November 2022 — Board independence, honoraria and conflict-disclosure scope.
- NHS national content policy, October 2022 — Website funding and editorial safeguards only.
Educational research reviewed 4 October 2026. Diagnosis and treatment require a qualified clinician; this article does not provide an individual prescription or replace urgent assessment.
Have a question — or want us to cover something?
Ask about anything on this page, or request the next deep dive: an ingredient, a supplement, or a health concern. We use published research, evidence syntheses, and regulatory guidance, with clear source links.
One daily research roundup
Get the topics, key findings and links from our new articles in one email. At most one digest a day, only when there is something new.